Jabrehoo secures RMB100m Series B+

Jabrehoo, a reproductive genetic integration services company, has recently completed a Series B+ round of financing worth nearly 100 million yuan. The was exclusively invested by Apricot Capital, with Haoyue Capital serving as the sole financial advisor.

Jabrehoo, a reproductive genetic integration services company, has recently completed a Series B+ round of financing worth nearly 100 million yuan. The was exclusively invested by Apricot Capital, with Haoyue Capital serving as the sole financial advisor.

Proceeds from this round of financing will be used mainly for the research and development of innovative products in the field of reproductive genetics and the overall promotion of the integrated service platform.

Founded in 2011, Jabrehoo focuses on clinical translation and innovative research and development in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for assisted reproduction couples, infertility patients and pregnancy preparation groups.

The company’s products include high-throughput sequencing-based inspection products and non-sequencing products including related equipment, consumables, and management software.

Liu Wenyi, founding partner of Apricot Capital, the round’s investor, said, “Assisted reproduction and NGS are our long-term bullish tracks, and Jabrehoo is the first company in China to introduce NGS technology into assisted reproduction, using advanced technology to tap into the growing market, which is very much in line with our investment philosophy.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/12/jabrehoo-secures-rmb100m-series-b/.

Leave a Reply

Please Login to Comment